Life Science Update | December 2025
Purdue Pharma’s $7.4 Billion Chapter 11 Plan Formally Approved Eric Furman, Ph.D. & Rhett D. Ramsey A federal bankruptcy court on November 18 formally approved Purdue’s $7.4 billion Chapter 11...
USPTO’s Automated Search Pilot: Through a Biotech Lens
In October 2025, the U.S. Patent and Trademark Office (USPTO) launched the “Artificial Intelligence Search Automated Pilot Program,” or ASAP!, an initiative to identify potential prior art using artificial intelligence...
Life Science Update | August 2025
Eyeing the Prize of the U.S. Patent System, the Trump Administration Proposes Patent Maintenance Fee Overhaul Jane Dai, Ph.D. & Susan M. Janicki, Ph.D. The Trump administration is considering changing the U.S....
CRISPR Dispute Heats Up With Recent Federal Court Decision
On May 12, 2025, the U.S. Court of Appeals for the Federal Circuit (CAFC) revived the Regents of the University of California’s (Regents) challenge to the Broad Institute’s CRISPR-Cas9 patents,...
Claims Reciting Material Properties of a Claimed Composition Withstand § 101 Scrutiny
US SYNTHETIC CORP. v. INTERNATIONAL TRADE COMMISSION Before Dyk, Chen, and Stoll. Appeal from the U.S. International Trade Commission. Summary: The Federal Circuit found claims reciting magnetic properties of a...
Heading Towards an Optimistic Initial Public Offerings (IPOs) Resurgence in 2025?
On January 16th, 2025, GT Medical Technologies, announced that it has raised $37 million in Series D financing round. The financing round was led by Evidity Health Capital and joined...
Being Known Is Not Enough
VIRTEK VISION INTERNATIONAL ULC, v. ASSEMBLY GUIDANCE SYSTEMS, INC., DBA ALIGNED VISION
Before Moore, Hughes, and Stark. Appeal from the Patent Trial and Appeal Board (“Board”).
Summary: Merely showing that prior art elements were known to a person skilled in the art without providing a reason to combine the references does not prove obviousness.
Is Evidence of Generic Industry Skepticism Enough to Preclude a Finding of a Motivation to Combine?
AURIS HEALTH, INC., v. INTUITIVE SURGICAL OPERATIONS, INC.,
Before Dyk, Prost, and Reyna. Appeal from the Patent Trial and Appeal Board (PTAB).
Summary: Evidence of generic industry skepticism cannot, by itself, form the basis to preclude a finding of motivation to combine.
Knobbe Martens Welcomes New Class of Associates
Knobbe Martens announces its continued commitment to providing the highest quality legal services with the addition of 30 new Associates firmwide. “Our new associates have a wide range of talents...
